Prostate Cancer Detection in the “Grey Area” of Prostate-Specific Antigen Below 10 ng/ml: Head-to-Head Comparison of the Updated PCPT Calculator and Chun’s Nomogram, Two Risk Estimators Incorporating Prostate Cancer Antigen 3-Reference-Cited by-同舟云学术

Prostate Cancer Detection in the “Grey Area” of Prostate-Specific Antigen Below 10 ng/ml: Head-to-Head Comparison of the Updated PCPT Calculator and Chun’s Nomogram, Two Risk Estimators Incorporating Prostate Cancer Antigen 3

Published:2011-01 Issue:1 Volume:59 Page:81-87
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Perdonà Sisto,Cavadas Vitor,Di Lorenzo Giuseppe,Damiano Rocco,Chiappetta Gennaro,Del Prete Paola,Franco Renato,Azzarito Giuseppina,Scala Stefania,Arra Claudio,De Sio Marco,Autorino Riccardo

Publisher

Elsevier BV

Subject

Urology

Reference18 articles.

1. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review;Schröder;Eur Urol,2008

2. Urinary prostate cancer 3 test: toward the age of reason?;Vlaeminck-Guillem;Urology,2010

3. Predicting prostate cancer risk through incorporation of prostate cancer gene 3;Ankerst;J Urol,2008

4. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram;Chun;Eur Urol,2009

5. Risk of biopsy-detectable prostate cancer. University of Texas Health Science Center San Antonio Web site. http://deb.uthsca.edu/URORiskCalc/Pages/uroriskcalc.jsp. Accessed June 2010.

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison between the European Randomized Study for Screening of Prostate Cancer (ERSPC) and Prostate Biopsy Collaborative Group (PBCG) risk calculators: Prediction of clinically significant Prostate Cancer risk in a cohort of patients from Argentina;Actas Urológicas Españolas (English Edition);2023-10

2. Nanotheranostics: Platforms, Current Applications, and Mechanisms of Targeting in Breast and Prostate Cancers;Journal of Nanotheranostics;2023-08-10

3. Comparación entre las calculadoras de riesgo del European Randomized Study for Screening of Prostate Cancer (ERSPC) y Prostate Biopsy Collaborative Group (PBCG): predicción del riesgo de cáncer de próstata clínicamente significativo en una cohorte de pacientes de Argentina;Actas Urológicas Españolas;2023-08

4. Biomolecule-functionalized nanoformulations for prostate cancer theranostics;Journal of Advanced Research;2022-11

5. A smart, practical, deep learning-based clinical decision support tool for patients in the prostate-specific antigen gray zone: model development and validation;Journal of the American Medical Informatics Association;2022-08-30